Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells

Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin lymphoma which is the 7th most common cancer type in the US and UK, and conversely, Hodgkin lymphoma which constitutes 0.5-1% of all cancers reported in the US and UK. Treatment strategies depend on the type of lymphoma, as well as location and staging. Recent treatment developments include novel chemotherapy agents and immunotherapies including CAR T-cells and antibody-drug conjugates. In this podcast, Wendy Osborne, of Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Peter Borchmann, from the University Hospital Cologne, Cologne, Germany, and Caron Jacobson, of the Dana-Farber Cancer Institute, Boston, MA, discuss updates in the lymphoma field presented at this year’s virtual meeting.

The post Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells appeared first on VJHemOnc.